Hemochromatosis Does Not Increase Lipoprotein(a) Levels
Hereditary hemochromatosis (HH) does not cause elevated lipoprotein(a) [Lp(a)] levels. The available evidence shows no association between HH and Lp(a) elevation, and the two conditions involve entirely separate pathophysiological mechanisms.
Evidence Supporting No Association
The provided research evidence examining HH focuses extensively on lipid metabolism abnormalities, but none of the studies investigating lipid profiles in HH patients report any effect on Lp(a) levels 1, 2, 3.
Lipid Abnormalities Actually Present in Hemochromatosis
While HH does not affect Lp(a), it does cause other lipid disturbances:
Hypertriglyceridemia is the primary lipid abnormality in HH, occurring in approximately 31.6% of patients with iron overload 2.
Phospholipid metabolism is altered, with significantly lower phosphatidylcholine (PC) and higher phosphatidylethanolamine (PE), resulting in a decreased PC/PE ratio 1.
Triglyceride levels improve with therapeutic phlebotomy, decreasing from 287 mg/dL to 133 mg/dL in patients with baseline hypertriglyceridemia once ferritin drops below 200 μg/L and transferrin saturation falls below 40% 2.
HFE mutations (C282Y and H63D) are associated with primary hypertriglyceridemia, with genetic predisposition to HH being 5.9 times higher in hypertriglyceridemic patients compared to normolipemic controls 3.
Lipoprotein(a) Genetics Are Independent
Lp(a) levels are determined by entirely different genetic factors that have no overlap with HH genetics:
Lp(a) concentration is primarily controlled by the LPA gene, which encodes apolipoprotein(a) and contains variable kringle IV-2 domain repeats resulting in over 40 different isoform sizes 4.
Other genetic loci affecting Lp(a) include APOE and APOH, but not HFE 4.
Lp(a) levels are 90% genetically determined and remain stable throughout adult life, unaffected by iron metabolism 5.
Clinical Implications
If you encounter a patient with both HH and elevated Lp(a):
These are coincidental findings, not causally related, as both conditions are relatively common in populations of northern European descent 5.
Manage each condition independently: therapeutic phlebotomy for HH to prevent cirrhosis, hepatocellular carcinoma, diabetes, and heart disease 5; and aggressive LDL-C lowering for elevated Lp(a) to reduce cardiovascular risk 5.
Screen for Lp(a) based on standard indications: premature CVD, family history of premature CVD, recurrent CVD despite optimal therapy, or ≥5% 10-year cardiovascular risk, using thresholds of >30 mg/dL or >75 nmol/L 5.